Company: IPSC
Filing Date: 2025-02-28
Form Type: 8-K
Source: 0001104659-25-019145
Chunk: 0

Company: Century Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 8-K
Item: Item 3.01
Chunk 0
---
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing.

On February 26, 2025, Century Therapeutics, Inc. (the “ Company”)
received a notification letter (the “ Bid Price Letter”) from The Nasdaq Stock Market LLC (“ Nasdaq”) notifying
the Company that, for the last 31 consecutive business days, the closing bid price for the Company’s common stock has been below
the minimum $1.00 per share required for continued listing on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1)
(“ Rule 5450(a)(1)”). The Bid Price Letter is a notice of deficiency, not delisting, and does not currently affect the listing
or trading of the Company’s shares of common stock on The Nasdaq Global Select Market.

The Company has 180 days, or until August 25, 2025, to comply
with Rule 5450(a)(1) by maintaining a closing bid price of at least $1.00 per share for at least 10 consecutive business days,
and the Company must otherwise satisfy the Nasdaq Global Select Market’s requirements for listing. If the Company
has not been deemed in compliance prior to the expiration of the 180 day period, the Company may transfer to the Nasdaq Capital Market,
provided that it meets the applicable market value of publicly held shares requirement for continued listing and all other applicable
requirements for initial listing on the Nasdaq Capital Market (except for the bid price requirement) based on the Company’s
most recent public filings and market information and notifies Nasdaq of its intent to cure this deficiency. Following a transfer to the
Nasdaq Capital Market, the Company would be afforded the remainder of the applicable compliance period set forth in Nasdaq Listing Rule
5810(c)(3)(A)(ii) which provides an additional 180 days’ compliance period, unless it does not appear to Nasdaq that it is
possible for the Company to cure the deficiency.

The Company intends to monitor closely the closing bid price of its
common stock and to consider plans for regaining compliance with Rule 5450(a)(1). While the Company plans to review all available options,
there can be no assurance that it will be able to regain compliance with Rule 5450(a)(1) during the 180 day compliance period, any subsequent
extension period, or at all.

Forward-Looking Statements